0001029142FALSE00010291422025-02-032025-02-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________________________
FORM 8-K
______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 3, 2025
    
______________________________________________________
Dynavax Technologies Corporation
(Exact name of Registrant as Specified in Its Charter)
______________________________________________________
Delaware001-3420733-0728374
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)

2100 Powell Street, Suite 720
Emeryville, CA
94608
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (510) 848-5100
(Former Name or Former Address, if Changed Since Last Report)
______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par valueDVAXNasdaq Global Select Market
Preferred Share Purchase Rights
N/A
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 3, 2025, Justin Burgess notified Dynavax Technologies Corporation (the “Company”) that he intends to resign from the Company, including his position as the Company’s principal accounting officer, on or about March 3, 2025. The Company intends to appoint Kelly MacDonald, the Company’s Chief Financial Officer and principal financial officer, as the Company’s principal accounting officer, prior to March 3, 2025.
There will be no change in Ms. MacDonald’s compensation as a result of this appointment. Biographical information for Ms. MacDonald is available in the Company’s proxy statement filed with the Securities and Exchange Commission on April 11, 2024 in connection with the Company’s 2024 annual meeting of stockholders, such information being incorporated herein by reference.
There are no arrangements or understandings between Ms. MacDonald and any other persons in connection with Ms. MacDonald’s appointment as a principal accounting officer. There are also no family relationships between Ms. MacDonald and any director or executive officer of the Company and Ms. MacDonald has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dynavax Technologies Corporation
Date:
February 7, 2025
By: /s/ RYAN SPENCER
Ryan Spencer
Chief Executive Officer

v3.25.0.1
Document And Entity Information
Feb. 03, 2025
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 03, 2025
Entity Registrant Name Dynavax Technologies Corporation
Entity Incorporation, State or Country Code DE
Entity File Number 001-34207
Entity Tax Identification Number 33-0728374
Entity Address, Address Line One 2100 Powell Street
Entity Address, Address Line Two Suite 720
Entity Address, City or Town Emeryville
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code 510
Local Phone Number 848-5100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol DVAX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001029142
Amendment Flag false
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Dynavax Technologies Charts.
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Dynavax Technologies Charts.